Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-22T07:12:40.677Z Has data issue: false hasContentIssue false
  • English
  • Français

Which atypical antipsychotic?

Published online by Cambridge University Press:  02 January 2018

Christopher S. Thomas  and
Shôn Lewis
Christopher S. Thomas*
Affiliation:
University Hospital of South Manchester, Manchester M20 8LR
Shôn Lewis
Affiliation:
University Hospital of South Manchester, Manchester M20 8LR
*
Dr Christopher Thomas, Consultant Psychiatrist. University Hospital of South Manchester, Nell Lane. Manchester M20 8LR
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorials
Information
The British Journal of Psychiatry , Volume 172 , Issue 2 , February 1998 , pp. 106 - 109
Copyright
Copyright © 1998 The Royal College of Psychiatrists 

References

Addington, D. E. Jones, B. Bloom, D. et al (1993) Reduction in hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clinical Therapeutics. 15, 917–926.Google Scholar
Almond, S. & O'Donnell, O. (1998) The cost effectiveness of olanzapine compared with haloperidol in the treatment of schizophrenia in the UK. Journal of Pharmacoeconomics, in press.Google Scholar
Ames, D. Wirshing, W. C. Marshall, B. D. et al (1997) Risperidone v haloperidol in treatment resistant schizophrenia. Schizophrenia Research, 24. 193–194.Google Scholar
Andreasen, N. C. (1982) Negative symptoms in schizophrenia. Archives of General Psychiatry, 39, 784–788 CrossRefGoogle ScholarPubMed
Arvanitis, L. A. Miller, B. G. & the Seroquel Trial 13 Study Group (1997) Multiple fixed doses of “seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. biological Psychiatry, 42. 233–246.CrossRefGoogle ScholarPubMed
Barnett, A. (1996) Safety concerns over antipsychotic drugs; sertindole. Lancet, 348, 256.Google Scholar
Beasley, C. M. Tollefson, M. D. Tran, P. et al (1996a) Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14, 111–123.Google Scholar
Beasley, C. M. Sanger, T. Satterlee, W. et al (1996b) Olanzapine versus placebo: results of a double blind fixed-dose olanzapine trial. Psychopharmacology, 124, 159–167 CrossRefGoogle ScholarPubMed
Bondolfi, G. Baumann, P. & Dufour, H. (1996) Treatment-resistant schizophrenia: clinical experience with new antipsychotics. European Neuropsychopharmacology 6 (suppl. 2). S2–S25.Google Scholar
Breier, A. Buchanan, R. W. Kirkpatrick, B. et al (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry, 151, 20–26.Google Scholar
Carman, J. Peuskens, J. & Vangeneugden, A. (1995) Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. International Journal of Psychopharmacology, 10, 207–213.Google Scholar
Carpenter, W. T. Conley, R. Buchanan, R. W. et al (1995) Patient response and resource management: another view of clozapine treatment of schizophrenia. American Journal of Psychiatry, 152. 827–832.Google Scholar
Casey, D. E. (1996) Extrapyramidal symptoms in old and new antipsychotics. Journal of Clinical Psychiatry, 57. 433–436.Google Scholar
Conley, R. Tamminga, C. A. & Beasley, C. (1997) Olanzapine vs. chlorpromazine in therapy refractory schizophrenia. Schizophrenia Research, 24, 190.Google Scholar
Davies, L. M. & Drummond, M. E. (1993) Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. British Journal of Psychiatry, 162, 38–42 Google Scholar
Davis, R. & Markham, A. (1997) Ziprasidone CNS Drugs, 8, 153–159.CrossRefGoogle ScholarPubMed
Kane, J. Honigfeld, G. Singer, J. et al (1988) Clozapine for treatment resistant schizophrenia: a double blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789–796.Google Scholar
Kay, S. R. Fiszbein, A. & Opier, L.A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.CrossRefGoogle ScholarPubMed
King, D. J. (1994) Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiatrica Scandinavica, 89 (suppl. 380). 53–58.Google Scholar
Lieberman, J. A. Safferman, A. Z. Pollack, S. et al (1994) Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. American Journal of Psychiatry, 151, 1744–1752.Google Scholar
Marder, S.R. & Meibach, R.C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825–835.Google ScholarPubMed
Mattes, J. A. (1997) Risperidone: how good is the evidence of efficacy? Schizophrenia Bulletin, 23. 155–161.Google Scholar
Meitzer, H.Y. & Okali, G. (1995) The reduction of suicidality during clozapine treatment in neuroleptic resistant schizophrenia: impact on risk–benefit assessment. American Journal of Psychiatry, 152, 183–190.Google Scholar
Overall, J.E. & Gorham, D.R. (1962) The brief psychiatric rating scale. Psychological Reports, 10, 799–812.Google Scholar
Peuskens, J. on behalf of the Risperidone Study Group (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multicentre, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry, 166, 712–726.Google Scholar
Revicki, D. A. Luce, B. R. Weschler, J. M. et al (1990) Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hospital and Community Psychiatry, 41, 850–854.Google Scholar
Small, J. G. Hirsch, S. R. Arvanitis, L. A. et al (1997) Quetiapine in patients with schizophrenia: a high and low dose double-blind comparison with placebo. Archives of General Psychiatry, 54, 549–557.CrossRefGoogle ScholarPubMed
Song, F. (1997) Risperidone in the treatment of schizophrenia: a meta-analysis of randomised controlled trials. Journal of Psychopharmacology, 11, 65–71.Google Scholar
Tollefson, G. D. & Sanger, T. M. (1997) Negative symptoms: a path analytic approach to a double blind, placebo- and haloperidol-controlled clinical trial with olanzapine. American Journal of Psychiatry, 154, 466–474.Google ScholarPubMed
Tollefson, G.D. Beasley, C.M. Tran, R.V. et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 154, 457–465.Google Scholar
Umbricht, D. Ames, D. Wirshing, W. C. et al (1997) Predictors of response to clozapine in a long-term double blind treatment study. Schizophrenia Research, 24, 189.Google Scholar
Zimbroff, D. L. Kane, J. M. Tamminga, C. A. et al (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry, 154, 782–791.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.